Brandon Van Dyke
Brandon Van Dyke focuses his practice on mergers and acquisitions and corporate and securities law matters.

Bio

Mr. Van Dyke has represented acquirers, targets and financial advisors in a number of significant U.S. and cross-border mergers, acquisitions, takeovers (both negotiated and contested), leveraged buyouts and other corporate matters. In addition, he has provided transactional advice to companies implementing corporate restructuring plans.

Industries in which Mr. Van Dyke has had substantial transactional involvement include media and entertainment, mining and metals, chemicals, pharmaceutical and health care.

In 2017, he was named as a Rising Star by New York Law Journal. In 2016, Mr. Van Dyke was named a Dealmaker of the Year by The American Lawyer and was named an M&A Rising Star”by Law360. Additionally, in 2012, The M&A Advisor selected him as one of the top 40 M&A professionals under the age of 40.

Representations and transactions include:

  • DuPont in numerous transactions, including:

    • its announced $130 billion “merger of equals” transaction with The Dow Chemical Company;
    • responding to a proxy contest commenced by Trian Fund Management, L.P., a representation recognized in the Financial Times’ 2015 North America “Innovative Lawyers” report;
    • the tax-free spin-off of its global performance chemicals business into a separate public company;
    • its $4.9 billion sale of DuPont Performance Coatings to The Carlyle Group; and
    • its $6.6 billion acquisition of Danisco A/S by tender offer, one of the largest transactions in the history of Denmark up to that time;
  • Twenty-First Century Fox in its proposed, but terminated, $80 billion acquisition of Time Warner;
  • Endo Health Solutions in its $1.6 billion acquisition of Paladin Labs Inc. (Canada) through the formation of a new Irish holding company;
  • News Corporation in numerous transactions, including:

    • the $12 billion tax-free spin-off of its newspapers, information services and certain other operations into a separate public company;
    • its $11.5 billion proposed, but terminated, acquisition of the remaining stake it did not already own in British Sky Broadcasting Group plc;
    • in partnership with Permira Advisers Ltd., a private equity firm in the United Kingdom, in their $3.7 billion going-private acquisition of NDS Group plc;
    • in its $5.6 billion acquisition of Dow Jones & Company;
    • in its $11 billion buyback of its stock from Liberty Media in exchange for cash and assets; and
    • in taking Fox Entertainment Group private for $6 billion in News Corporation stock;
  • Gilead Sciences, Inc. in its $11 billion acquisition of Pharmasset, Inc., a transaction that was recognized in the 2012 Financial Times “US Innovative Lawyers” report;
  • Endo Pharmaceuticals in its $2.9 billion acquisition of American Medical Systems;
  • Endo Pharmaceuticals Holdings in its $1.2 billion acquisition of Qualitest (a portfolio company of Apax Partners) and in its $250 million acquisition of HealthTronics, Inc. by tender offer;
  • Medtronic, Inc. in its $487 million sale of its Physio-Control division to affiliates of Bain Capital, LLC;
  • Dow Jones & Company in its $675 million financial index joint venture with CME Group;
  • CIT Group in a cash debt tender offer in connection with its restructuring plan;
  • Express Scripts in its $4.675 billion acquisition of WellPoint Inc.’s NextRx subsidiaries;
  • Safeco in its $6.2 billion merger with Liberty Mutual Insurance Company;
  • Alcoa Inc. in its commenced, but terminated, $27 billion hostile exchange offer for Alcan Inc.;
  • Serono S.A. and the Bertarelli family in the €10.6 billion acquisition of Serono by Merck KGaA;
  • Marathon Fund in its proposed, but terminated, $1 billion acquisition of Shopko Stores, Inc.;
  • AMC Entertainment, Inc. in its $2 billion sale to J.P. Morgan Partners and Apollo Partners Limited; and
  • AdvancePCS in its $6 billion merger with CaremarkRx, Inc.

Mr. Van Dyke also has advised several of Skadden’s investment banking clients as financial advisors in various public merger and acquisition transactions, including Goldman Sachs, Bank of America/Merrill Lynch and JPMorgan Chase as financial advisors to Pfizer in its $68 billion merger with Wyeth.

In addition, Mr. Van Dyke has advised clients with respect to responding to unsolicited acquisition proposals, stockholder activist approaches and other corporate preparedness matters, SEC reporting obligations, board governance, and other corporate and securities law matters.

Credentials

Education

  • J.D., Harvard Law School, 2001
  • B.A., Columbia University, Columbia College, 1998 (magna cum laude)

Admissions

  • New York

Brandon Van Dyke

Partner, Mergers and Acquisitions
brandon.vandyke@skadden.com